- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,390 | 21.06.24 17:35:41 | -0,740 | -0,84% | 0,000 | 0,000 | 87,920 | 87,390 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.053,140 | 21.06.24 23:04:46 | +8,915 | +0,85% | 1.053,660 | 1.075,000 | 1.047,710 | 1.053,140 |
